ACW commences open-label phase of XanaMIA Alzheimer’s trialLikeFollowShareView the company's US newswire published 1 April 2026https://www.globenewswire.com/news-release/2026/04/01/3266624/0/en/actinogen-commences-open-label-phase-of-xanamia-alzheimer-s-trial-and-provides-business-update.htmlShare your feedbackQuestions (0)Post questionYour question will be sent privately to Actinogen. The company may choose to make this question public.Start the conversationAsk Actinogen a question about this update.DiscoverShare your feedbackDiscover
